Program
claturafenib
Also written as “PF-07799933”, “PF-07799933 tablets with PF-07799544 fasted” and “PF-07799933 film-coated tablets with PF-07799544 fasted”.
In Pfizer's pipeline, BRAF Class 1 and Class 2 inhibitor
. Its studies are mostly in Melanoma, led by Pfizer.
Furthest: phase 1, since Apr 26, 20222 company-led studies, 1 open or runningNext primary completion: Aug 31, 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Pfizer | 21 open or running | phase 1since Apr 26, 2022 | Apr 26, 2022 | Aug 31, 2027phase 1 · NCT05355701 |
- Named in Pfizer’s own pipeline as
claturafenib PF-07799933
, phase 1, as of Nov 3, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 26, 2022First study: phase 1 study in MelanomaFirst studyNCT05355701 · 103 enrolled · United States, Canada, Israel
- Apr 6, 2026Phase 1 study in HealthyNCT07563894 · 16 enrolled · United States
Ahead
- Aug 31, 2027Primary completion: phase 1 study in MelanomaNCT05355701
TargetBeta
“BRAF Class 1 and Class 2 inhibitor”the company's pipeline, read by Claude · source
“An orally bioavailable class 1 and 2 inhibitor of the serine/threonine-protein kinase B-raf (BRAF) protein, with potential antineoplastic activity. Upon oral administration, claturafenib selectively binds to and inhibits the activity of class 1 and 2 BRAF alterations. This inhibits the proliferat…”NCIt, read by Claude
“An orally bioavailable class 1 and 2 inhibitor of the serine/threonine-protein kinase B-raf (BRAF) protein, ”NCIt, by rule
Other programs on BRAF
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| regorafenibrule | Bayer | phase 4 | 40 |
| tovorafenibrule | day-one-biopharmaceuticals-inc | phase 3 | 8 |
| BRAF V600E Inhibitor HLX208 | Fosun Pharma | phase 2 | 12 |
| belvarafenibrule | Hanmi Pharmaceutical | phase 2 | 6 |
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07563894Healthy · United States | 1 | Completed | Jun 24, 2026 | 16 |
| NCT05355701Melanoma · United States, Canada, Israel | 1 | Active, not recruiting | Aug 31, 2027 | 103 |
How it is read
Names in the registry
- “PF-07799933”, 1 entry
- “PF-07799933 tablets with PF-07799544 fasted”, 1 entry
- “PF-07799933 film-coated tablets with PF-07799544 fasted”, 1 entry
- “PF-07799933 film-coated tablets with PF-07799544 fed”, 1 entry
- “PF-07799933 film-coated tablets fasted”, 1 entry
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.